U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C26H28Cl2N4O4
Molecular Weight 531.4318
Optical Activity ( + / - )
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of KETOCONAZOLE

SMILES

CC(=O)N1CCN(CC1)c2ccc(cc2)OC[C@]3([H])CO[C@@](Cn4ccnc4)(c5ccc(cc5Cl)Cl)O3

InChI

InChIKey=XMAYWYJOQHXEEK-ZEQKJWHPSA-N
InChI=1S/C26H28Cl2N4O4/c1-19(33)31-10-12-32(13-11-31)21-3-5-22(6-4-21)34-15-23-16-35-26(36-23,17-30-9-8-29-18-30)24-7-2-20(27)14-25(24)28/h2-9,14,18,23H,10-13,15-17H2,1H3/t23-,26-/m1/s1

HIDE SMILES / InChI

Molecular Formula C26H28Cl2N4O4
Molecular Weight 531.4318
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: Description was created based on several sources, including http://press.endocrine.org/doi/abs/10.1210/endo-meetings.2016.NP.15.SAT-547 | https://www.ncbi.nlm.nih.gov/pubmed/18640464 | https://www.ncbi.nlm.nih.gov/pubmed/25000292

2S,4R ketoconazole or levoketoconazole is the 2S,4R enantiomer of ketoconazole, purified from racemic ketoconazole. Both enantiomers exerts antifungal activity. Ketoconazole activates AhR in gene reporter cell line and dose-dependently induces CYP1A1 mRNA and CYP1A1 protein in HepG2 cells, with enantiospecific pattern, i.e. 2R,4S ketoconazole was much more active as compared to 2S,4R ketoconazole. Levoketoconazole was shown to be a more potent inhibitor than the 2R,4S enantiomer of several enzymes in the steroidogenic pathway (CYP11B1, CYP17 and CYP21). Levoketoconazole was tested for the treatment of endogenous Cushing’s syndrome (Phase III) and type 2 diabetes mellitus (Phase II).

CNS Activity

Curator's Comment:: Ketoconazole does not cross the intact blood-brain barrier, and crosses to only a limited extent in fungal meningitis.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
NIZORAL

Approved Use

Ketoconazole Cream, 2% is indicated for the topical treatment of tinea corporis, tinea cruris and tinea pedis caused by Trichophyton rubrum, T. mentagrophytes and Epidermophyton floccosum; in the treatment of tinea (pityriasis) versicolor caused by Malassezia furfur (Pityrosporum orbiculare); in the treatment of cutaneous candidiasis caused by Candida spp. and in the treatment of seborrheic dermatitis.

Launch Date

3.61151988E11
Curative
NIZORAL

Approved Use

Ketoconazole Cream, 2% is indicated for the topical treatment of tinea corporis, tinea cruris and tinea pedis caused by Trichophyton rubrum, T. mentagrophytes and Epidermophyton floccosum; in the treatment of tinea (pityriasis) versicolor caused by Malassezia furfur (Pityrosporum orbiculare); in the treatment of cutaneous candidiasis caused by Candida spp. and in the treatment of seborrheic dermatitis.

Launch Date

3.61151988E11
Curative
NIZORAL

Approved Use

Ketoconazole Cream, 2% is indicated for the topical treatment of tinea corporis, tinea cruris and tinea pedis caused by Trichophyton rubrum, T. mentagrophytes and Epidermophyton floccosum; in the treatment of tinea (pityriasis) versicolor caused by Malassezia furfur (Pityrosporum orbiculare); and in the treatment of cutaneous candidiasis caused by Candida spp.

Launch Date

3.61151988E11
Curative
NIZORAL Tablets

Approved Use

NIZORAL Tablets should be used only when other effective antifungal therapy is not available or tolerated and the potential benefits are considered to outweigh the potential risks. NIZORAL (ketoconazole) Tablets are indicated for the treatment of the following systemic fungal infections in patients who have failed or who are intolerant to other therapies: blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis. NIZORAL Tablets should not be used for fungal meningitis because it penetrates poorly into the cerebrospinal fluid.

Launch Date

3.61151988E11
Curative
NIZORAL Tablets

Approved Use

NIZORAL Tablets should be used only when other effective antifungal therapy is not available or tolerated and the potential benefits are considered to outweigh the potential risks. NIZORAL (ketoconazole) Tablets are indicated for the treatment of the following systemic fungal infections in patients who have failed or who are intolerant to other therapies: blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis. NIZORAL Tablets should not be used for fungal meningitis because it penetrates poorly into the cerebrospinal fluid.

Launch Date

3.61151988E11
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
6 μg/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
KETOCONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
3.5 μg/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
KETOCONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1053 mg × min/L
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
KETOCONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
122 min
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
KETOCONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2 h
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
KETOCONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
KETOCONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
Doses

Doses

DosePopulationAdverse events​
400 mg 3 times / day multiple, oral
Highest studied dose
Dose: 400 mg, 3 times / day
Route: oral
Route: multiple
Dose: 400 mg, 3 times / day
Sources:
unhealthy, 64.8 years (range: 52-80 years)
n = 28
Health Status: unhealthy
Condition: relapsing prostatic cancer
Age Group: 64.8 years (range: 52-80 years)
Sex: M
Population Size: 28
Sources:
Disc. AE: Gastrointestinal disorders, Gastrointestinal disorders...
Other AEs: Itching, Dry skin...
AEs leading to
discontinuation/dose reduction:
Gastrointestinal disorders (severe, 4 patients)
Gastrointestinal disorders (severe, 3 patients)
Other AEs:
Itching (3 patients)
Dry skin (3 patients)
Sources:
2 % 1 times / day multiple, topical
Recommended
Dose: 2 %, 1 times / day
Route: topical
Route: multiple
Dose: 2 %, 1 times / day
Sources:
unhealthy, adult
n = 545
Health Status: unhealthy
Condition: seborhheic dermatitis
Age Group: adult
Population Size: 545
Sources:
Other AEs: Application site burning, Headache...
Other AEs:
Application site burning (4.2%)
Headache (1.1%)
Sources:
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adult
Other AEs: Hepatotoxicity...
Other AEs:
Hepatotoxicity (serious|grade 5)
Sources:
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Co-administed with::
dofetilide
Sources:
unhealthy, adult
Other AEs: QT interval prolonged...
AEs

AEs

AESignificanceDosePopulation
Dry skin 3 patients
400 mg 3 times / day multiple, oral
Highest studied dose
Dose: 400 mg, 3 times / day
Route: oral
Route: multiple
Dose: 400 mg, 3 times / day
Sources:
unhealthy, 64.8 years (range: 52-80 years)
n = 28
Health Status: unhealthy
Condition: relapsing prostatic cancer
Age Group: 64.8 years (range: 52-80 years)
Sex: M
Population Size: 28
Sources:
Itching 3 patients
400 mg 3 times / day multiple, oral
Highest studied dose
Dose: 400 mg, 3 times / day
Route: oral
Route: multiple
Dose: 400 mg, 3 times / day
Sources:
unhealthy, 64.8 years (range: 52-80 years)
n = 28
Health Status: unhealthy
Condition: relapsing prostatic cancer
Age Group: 64.8 years (range: 52-80 years)
Sex: M
Population Size: 28
Sources:
Gastrointestinal disorders severe, 3 patients
Disc. AE
400 mg 3 times / day multiple, oral
Highest studied dose
Dose: 400 mg, 3 times / day
Route: oral
Route: multiple
Dose: 400 mg, 3 times / day
Sources:
unhealthy, 64.8 years (range: 52-80 years)
n = 28
Health Status: unhealthy
Condition: relapsing prostatic cancer
Age Group: 64.8 years (range: 52-80 years)
Sex: M
Population Size: 28
Sources:
Gastrointestinal disorders severe, 4 patients
Disc. AE
400 mg 3 times / day multiple, oral
Highest studied dose
Dose: 400 mg, 3 times / day
Route: oral
Route: multiple
Dose: 400 mg, 3 times / day
Sources:
unhealthy, 64.8 years (range: 52-80 years)
n = 28
Health Status: unhealthy
Condition: relapsing prostatic cancer
Age Group: 64.8 years (range: 52-80 years)
Sex: M
Population Size: 28
Sources:
Headache 1.1%
2 % 1 times / day multiple, topical
Recommended
Dose: 2 %, 1 times / day
Route: topical
Route: multiple
Dose: 2 %, 1 times / day
Sources:
unhealthy, adult
n = 545
Health Status: unhealthy
Condition: seborhheic dermatitis
Age Group: adult
Population Size: 545
Sources:
Application site burning 4.2%
2 % 1 times / day multiple, topical
Recommended
Dose: 2 %, 1 times / day
Route: topical
Route: multiple
Dose: 2 %, 1 times / day
Sources:
unhealthy, adult
n = 545
Health Status: unhealthy
Condition: seborhheic dermatitis
Age Group: adult
Population Size: 545
Sources:
Hepatotoxicity serious|grade 5
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adult
QT interval prolonged
200 mg 1 times / day steady, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Co-administed with::
dofetilide
Sources:
unhealthy, adult
PubMed

PubMed

TitleDatePubMed
Antimycotic imidazoles. part 4. Synthesis and antifungal activity of ketoconazole, a new potent orally active broad-spectrum antifungal agent.
1979 Aug
In vitro activity of ketoconazole against herpes simplex virus.
1986 Aug
Activity of SM-4470, a new imidazole derivative, against experimental fungal infections.
1986 Sep
Cilofungin (LY121019), an antifungal agent with specific activity against Candida albicans and Candida tropicalis.
1988 Sep
In vitro activity of cloconazole, sulconazole, butoconazole, isoconazole, fenticonazole, and five other antifungal agents against clinical isolates of Candida albicans and Candida spp.
1992 Apr
In vitro antifungal activities and in vivo efficacies of 1,3-beta-D-glucan synthesis inhibitors L-671,329, L-646,991, tetrahydroechinocandin B, and L-687,781, a papulacandin.
1992 Aug
Stereoisomers of ketoconazole: preparation and biological activity.
1992 Jul 24
In vitro comparative study of the fungistatic and fungicidal activity of sertaconazole and other antifungals against Candida albicans.
1992 May
Antifungal properties in a novel series of triazino[5,6-b]indoles.
1993 Jun
Effects of the combination of ketoconazole and calmodulin inhibitors against Candida albicans in vitro. Short communication.
1993 Sep
In vitro activity of a new pneumocandin antifungal agent, L-733,560 against azole-susceptible and -resistant Candida and Torulopsis species.
1995 Dec
In vitro susceptibility of filamentous fungi to itraconazole.
1995 Oct
In vitro antifungal and fungicidal activities and erythrocyte toxicities of cyclic lipodepsinonapeptides produced by Pseudomonas syringae pv. syringae.
1996 Dec
Antifungal activity of sertaconazole in vitro against clinical isolates of Candida spp.
1996 Mar-Apr
Isolation and characterisation of an antifungal antibiotic (GR135402) with protein synthesis inhibition.
1998 Jan
Synthesis and antimicrobial activity of some new benzimidazole carboxylates and carboxamides.
1999 Aug 30
Bactericidal and inhibitory effects of azole antifungal compounds on Mycobacterium smegmatis.
2000 Nov 15
Ciclopiroxolamine: in vitro antifungal activity against clinical yeast isolates.
2002 Nov
Selective anti-Toxoplasma gondii activities of azasterols.
2004 Jun
Identification of a novel antifungal nonapeptide generated by combinatorial approach.
2005 Apr
Prediction of genotoxicity of chemical compounds by statistical learning methods.
2005 Jun
Safety profile and metabolic effects of 14 days of treatment with DIO-902: results of a phase IIa multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in patients with type 2 diabetes mellitus.
2008 Jun
Antifungal triterpene glycosides from the sea cucumber Bohadschia marmorata.
2009 Feb
Bulky 1,4-benzoxazine derivatives with antifungal activity.
2009 Jun 1
Synergistic anticandidal activity of pure polyphenol curcumin I in combination with azoles and polyenes generates reactive oxygen species leading to apoptosis.
2010 Aug 1
Ketoconazole enantiomer for the treatment of diabetes mellitus.
2010 Feb
Fungicide activity of 5-(4-chlorobenzylidene)-(Z)-2-dimethylamino-1,3-thiazol-4-one against Cryptococcus neoformans.
2010 Jan
Synthesis, characterization and biocidal activity of new organotin complexes of 2-(3-oxocyclohex-1-enyl)benzoic acid.
2010 Mar
Synthesis and the selective antifungal activity of 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine derivatives.
2010 May
Design, synthesis and antifungal activities of novel 1,2,4-triazole derivatives.
2011 Jul
Practical synthesis, anticonvulsant, and antimicrobial activity of N-allyl and N-propargyl di(indolyl)indolin-2-ones.
2011 Jul 1
Antimicrobial, antimycobacterial and antibiofilm properties of Couroupita guianensis Aubl. fruit extract.
2012 Dec 4
Comparison of the effect of non-antifungal and antifungal agents on Candida isolates from the gastrointestinal tract.
2012 Jan
Antimicrobial activity of Ulopterol isolated from Toddalia asiatica (L.) Lam.: a traditional medicinal plant.
2012 Mar 6
Antifungal effect of ophthalmic preservatives phenylmercuric nitrate and benzalkonium chloride on ocular pathogenic filamentous fungi.
2013 Jan
Hippolachnin A, a new antifungal polyketide from the South China Sea sponge Hippospongia lachne.
2013 Jul 19
Synthesis and biological evaluation of pyrazoline derivatives bearing an indole moiety as new antimicrobial agents.
2013 Jun
Effects of chirality on the antifungal potency of methylated succinimides obtained by Aspergillus fumigatus biotransformations. comparison with racemic ones.
2013 May 15
3-Aryl-4-acyloxyethoxyfuran-2(5H)-ones as inhibitors of tyrosyl-tRNA synthetase: synthesis, molecular docking and antibacterial evaluation.
2013 Sep 1
Enantiospecific effects of ketoconazole on aryl hydrocarbon receptor.
2014
Synthesis and biological evaluation of novel N-substituted 1H-dibenzo[a,c]carbazole derivatives of dehydroabietic acid as potential antimicrobial agents.
2014 Jan 1
Synthesis and biological evaluation of thiazoline derivatives as new antimicrobial and anticancer agents.
2014 Mar 3
Updates on the role of adrenal steroidogenesis inhibitors in Cushing's syndrome: a focus on novel therapies.
2016 Dec
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: NIZORAL (ketoconazole) can be used topically: Usual Adult Dose for Cutaneous Candidiasis, Tinea Corporis, Tinea Cruris 2% Cream: Apply to the affected and immediate surrounding area once a day for 2 weeks. https://www.drugs.com/dosage/ketoconazole-topical.html
The recommended starting dose of NIZORAL (ketoconazole) Tablets is a single daily administration of 200 mg (one tablet). If clinical responsiveness is insufficient within the expected time, the dose of NIZORAL Tablets may be increased to 400 mg (two tablets) once daily
Route of Administration: Oral
In the case of ketoconazole, 50% inhibition of E. floccosum growth was achieved at 100 mg/L while 100% inhibition of growth was achieved at 200 mg/L. Ketoconazole was found to inhibit the growth of E. floccosum at 0.003-1.700 mg/L and was fungicidal at concentrations ranging from 0.027-1.700 mg/L.
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:59:21 UTC 2021
Edited
by admin
on Fri Jun 25 20:59:21 UTC 2021
Record UNII
R9400W927I
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
KETOCONAZOLE
EP   HSDB   INCI   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INN   USAN   INCI  
Official Name English
PIPERAZINE, 1-ACETYL-4-(4-((2-(2,4-DICHLOROPHENYL)-2-(1H-IMIDAZOL-1-YLMETHYL)-1,3-DIOXOLAN-4-YL)METHOXY)PHENYL)-, CIS-
Common Name English
KETOCONAZOLE [MART.]
Common Name English
R-41400
Code English
KETOCONAZOLE [USAN]
Common Name English
KETOCONAZOLE [MI]
Common Name English
KETOCONAZOLE [EP]
Common Name English
KETOCONAZOLE [EP MONOGRAPH]
Common Name English
KETOCONAZOLE [INCI]
Common Name English
NSC-317629
Code English
KETOCONAZOLE [USP]
Common Name English
J02AB02
Code English
(+/-)-CIS-1-ACETYL-4-(P-((2-(2,4-DICHLOROPHENYL)-2-(IMIDAZOL-1-YLMETHYL)-1,3-DIOXOLAN-4-YL)METHOXY)PHENYL)PIPERAZINE
Common Name English
KETOCONAZOLE [USP MONOGRAPH]
Common Name English
KETOCONAZOLE [USP-RS]
Common Name English
R 41,400
Code English
KETOZOLE
Brand Name English
EXTINA
Brand Name English
KETOCONAZOLE [JAN]
Common Name English
KETOCONAZOLE [ORANGE BOOK]
Common Name English
NIZORAL
Brand Name English
KETOCONAZOLE [INN]
Common Name English
KETOCONAZOLE [VANDF]
Common Name English
XOLEGEL
Brand Name English
KETOCONAZOLE [HSDB]
Common Name English
KETOCONAZOLUM [WHO-IP LATIN]
Common Name English
Classification Tree Code System Code
WHO-VATC QG01AF11
Created by admin on Fri Jun 25 20:59:21 UTC 2021 , Edited by admin on Fri Jun 25 20:59:21 UTC 2021
EMA ASSESSMENT REPORTS KETOCONAZOLE HRA (AUTHORIZED: CUSHING SYNDROME)
Created by admin on Fri Jun 25 20:59:21 UTC 2021 , Edited by admin on Fri Jun 25 20:59:21 UTC 2021
WHO-ATC D01AC08
Created by admin on Fri Jun 25 20:59:21 UTC 2021 , Edited by admin on Fri Jun 25 20:59:21 UTC 2021
FDA ORPHAN DRUG 51990
Created by admin on Fri Jun 25 20:59:21 UTC 2021 , Edited by admin on Fri Jun 25 20:59:21 UTC 2021
WHO-VATC QJ02AB02
Created by admin on Fri Jun 25 20:59:21 UTC 2021 , Edited by admin on Fri Jun 25 20:59:21 UTC 2021
NDF-RT N0000175487
Created by admin on Fri Jun 25 20:59:21 UTC 2021 , Edited by admin on Fri Jun 25 20:59:21 UTC 2021
WHO-VATC QD01AC08
Created by admin on Fri Jun 25 20:59:21 UTC 2021 , Edited by admin on Fri Jun 25 20:59:21 UTC 2021
LIVERTOX 532
Created by admin on Fri Jun 25 20:59:21 UTC 2021 , Edited by admin on Fri Jun 25 20:59:21 UTC 2021
WHO-ATC G01AF11
Created by admin on Fri Jun 25 20:59:21 UTC 2021 , Edited by admin on Fri Jun 25 20:59:21 UTC 2021
NDF-RT N0000008217
Created by admin on Fri Jun 25 20:59:21 UTC 2021 , Edited by admin on Fri Jun 25 20:59:21 UTC 2021
WHO-ATC J02AB02
Created by admin on Fri Jun 25 20:59:21 UTC 2021 , Edited by admin on Fri Jun 25 20:59:21 UTC 2021
EU-Orphan Drug EU/3/17/1857
Created by admin on Fri Jun 25 20:59:21 UTC 2021 , Edited by admin on Fri Jun 25 20:59:21 UTC 2021
NCI_THESAURUS C2018
Created by admin on Fri Jun 25 20:59:21 UTC 2021 , Edited by admin on Fri Jun 25 20:59:21 UTC 2021
Code System Code Type Description
USP_CATALOG
1356508
Created by admin on Fri Jun 25 20:59:21 UTC 2021 , Edited by admin on Fri Jun 25 20:59:21 UTC 2021
PRIMARY USP-RS
CAS
65277-42-1
Created by admin on Fri Jun 25 20:59:21 UTC 2021 , Edited by admin on Fri Jun 25 20:59:21 UTC 2021
PRIMARY
DRUG BANK
DB01026
Created by admin on Fri Jun 25 20:59:21 UTC 2021 , Edited by admin on Fri Jun 25 20:59:21 UTC 2021
PRIMARY
WIKIPEDIA
KETOCONAZOLE
Created by admin on Fri Jun 25 20:59:21 UTC 2021 , Edited by admin on Fri Jun 25 20:59:21 UTC 2021
PRIMARY
EVMPD
SUB08373MIG
Created by admin on Fri Jun 25 20:59:21 UTC 2021 , Edited by admin on Fri Jun 25 20:59:21 UTC 2021
PRIMARY
ChEMBL
CHEMBL295698
Created by admin on Fri Jun 25 20:59:21 UTC 2021 , Edited by admin on Fri Jun 25 20:59:21 UTC 2021
PRIMARY
RXCUI
6135
Created by admin on Fri Jun 25 20:59:21 UTC 2021 , Edited by admin on Fri Jun 25 20:59:21 UTC 2021
PRIMARY RxNorm
LACTMED
Ketoconazole
Created by admin on Fri Jun 25 20:59:21 UTC 2021 , Edited by admin on Fri Jun 25 20:59:21 UTC 2021
PRIMARY
INN
4594
Created by admin on Fri Jun 25 20:59:21 UTC 2021 , Edited by admin on Fri Jun 25 20:59:21 UTC 2021
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
KETOCONAZOLE
Created by admin on Fri Jun 25 20:59:21 UTC 2021 , Edited by admin on Fri Jun 25 20:59:21 UTC 2021
PRIMARY Description: A white or almost white powder. Solubility: Practically insoluble in water; freely soluble in dichloromethane R; soluble in methanol R; sparingly soluble in ethanol (~750 g/l) TS. Category: Antifungal drug. Storage: Ketoconazole should be kept in a well-closed container, protected from light. Requirement: Ketoconazole contains not less than 99.0% and not more than the equivalent of 101.0% of C26H28Cl2N4O4, calculated with reference to the dried substance.
IUPHAR
2568
Created by admin on Fri Jun 25 20:59:21 UTC 2021 , Edited by admin on Fri Jun 25 20:59:21 UTC 2021
PRIMARY
HSDB
7447
Created by admin on Fri Jun 25 20:59:21 UTC 2021 , Edited by admin on Fri Jun 25 20:59:21 UTC 2021
PRIMARY
MERCK INDEX
M6619
Created by admin on Fri Jun 25 20:59:21 UTC 2021 , Edited by admin on Fri Jun 25 20:59:21 UTC 2021
PRIMARY Merck Index
FDA UNII
R9400W927I
Created by admin on Fri Jun 25 20:59:21 UTC 2021 , Edited by admin on Fri Jun 25 20:59:21 UTC 2021
PRIMARY
NDF-RT
N0000190115
Created by admin on Fri Jun 25 20:59:21 UTC 2021 , Edited by admin on Fri Jun 25 20:59:21 UTC 2021
PRIMARY Cytochrome P450 3A5 Inhibitors [MoA]
NDF-RT
N0000182141
Created by admin on Fri Jun 25 20:59:21 UTC 2021 , Edited by admin on Fri Jun 25 20:59:21 UTC 2021
PRIMARY Cytochrome P450 3A4 Inhibitors [MoA]
DRUG CENTRAL
1527
Created by admin on Fri Jun 25 20:59:21 UTC 2021 , Edited by admin on Fri Jun 25 20:59:21 UTC 2021
PRIMARY
NDF-RT
N0000185503
Created by admin on Fri Jun 25 20:59:21 UTC 2021 , Edited by admin on Fri Jun 25 20:59:21 UTC 2021
PRIMARY P-Glycoprotein Inhibitors [MoA]
CAS
79156-75-5
Created by admin on Fri Jun 25 20:59:21 UTC 2021 , Edited by admin on Fri Jun 25 20:59:21 UTC 2021
NON-SPECIFIC STEREOCHEMISTRY
ECHA (EC/EINECS)
265-667-4
Created by admin on Fri Jun 25 20:59:21 UTC 2021 , Edited by admin on Fri Jun 25 20:59:21 UTC 2021
PRIMARY
EPA CompTox
65277-42-1
Created by admin on Fri Jun 25 20:59:21 UTC 2021 , Edited by admin on Fri Jun 25 20:59:21 UTC 2021
PRIMARY
MESH
D007654
Created by admin on Fri Jun 25 20:59:21 UTC 2021 , Edited by admin on Fri Jun 25 20:59:21 UTC 2021
PRIMARY
NCI_THESAURUS
C605
Created by admin on Fri Jun 25 20:59:21 UTC 2021 , Edited by admin on Fri Jun 25 20:59:21 UTC 2021
PRIMARY
Related Record Type Details
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INHIBITOR
METABOLIC ENZYME -> INHIBITOR
BINDER->LIGAND
BINDING
TARGET -> INHIBITOR
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
USP
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
TRANSPORTER -> SUBSTRATE
METABOLIC ENZYME -> INHIBITOR
IC50
METABOLIC ENZYME -> INHIBITOR
POTENT
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC